Compare Novavax Inc (NVAX) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs OneSpan Inc — how do they compare? Novavax Inc trades at $7.99 (market cap $1.31B), while OneSpan Inc trades at $16.31 (market cap $608.80M). The key difference: Novavax Inc is far larger — about 2.2× OneSpan Inc's market cap, and OneSpan Inc pays a 3.15% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | OSPN | |
|---|---|---|
Market Cap | $1.31B | $608.80M |
Sector | Health | Technology |
52-Week High | $11.19 | $16.78 |
52-Week Low | $6.22 | $10.15 |
Enterprise Value | $890.95M | $577.88M |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
OneSpan (OSPN) trades at $16.53, up 0.98% in the last session, with a bullish technical signal from moving averages. The stock shows strong profitability with a net income margin of 27.76% and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and the launch of DigipassONE, supporting growth in subscription revenue.
Outlook remains positive with a consensus price target of $17.00, though risks include declining net cash flow and competitive pressures. The stock offers value with a P/E of 9.21, but investors should monitor execution on guidance and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
